Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4480 Efficacy of regional and systemic therapies for refractory hypoglycaemia in malignant insulinoma

Introduction: Insulinoma is a rare neuroendocrine tumour characterised by inappropriate autonomous insulin secretion.

Conference:

Presenting Author: Koch R

Authors: Koch R, McGarrah P, Eiring R, Hobday T, Halfdanarson T,

Keywords: Insulinoma, radioligand therapy,

#4331 Amino acid-induced hyperkalaemia during peptide receptor radionuclide therapy (PRRT): A case report and literature review

Introduction: PRRT an established treatment for neuroendocrine tumours (NETs). Therapy requires prophylactic positively charged amino acid (AA) co-infusion to reduce renal radiation exposure. AA infusion has been associated with metabolic acidosis and electrolyte abnormalities, particularly hyperkalaemia; comprehensive data on the prevalence and severity of these complications remains limited.

Conference:

Presenting Author:

Authors: Osher E, Wolf I, Geva R, Sofer Y, Greenman Y,

Keywords: PRRT, hyperkalaemia, amino acid infusion, neuroendocrine tumour, adverse effects,

#4168 BRCA gene mutations and NEN – Is it just random or a meaningful coincidence?

Introduction: A BRCA mutation denotes a genetic alteration found in either the BRCA1 or BRCA2 genes, both of which function as tumor suppressors. BRCA mutations are widely acknowledged for their link to breast and ovarian cancers, and rarely, to other malignancies such as the pancreas and prostate. Noteworthy, there have been limited reports associating BRCA mutations with NEN, and no possible co-relation to certain racial/ethnic populations has been reported to date.

Conference:

Presenting Author: Bel-Ange A

Authors: Bel-Ange A, Maimon O, Grozinsky-Glasberg S,

Keywords: BRCA gene mutation, NEN-neuroendocrine neoplasm,

#4105 Long-term outcomes for medically managed carcinoid heart disease patients: A retrospective, longitudinal survey

Introduction: Carcinoid Heart Disease (CHD) is a component of carcinoid syndrome. Patients with mild to moderate CHD and no indication for surgical intervention receive medical management (MMCHD).

Conference:

Presenting Author:

Authors: Fisher J, Montague K, Adigun R, Hayes A, Furtado-O'Mahony L,

Keywords: carcinoid syndrome, carcinoid heart disease, survival, medical management,